---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence. Covers Pooled phase I/II analysis versus external control, CT-AMT-130-01, CT-AMT-130-02, and Planned confirmatory trial. 192 evidence topics quoted from 48 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Pooled Phase I/II Analysis versus External Control

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Pooled analysis protocols and prespecified external control comparison, September 2025

> “The ongoing Phase I/II AMT-130 clinical trials, from which the data herein are derived, are supplemented by two additional protocols, each with a statistical plan that was discussed with and submitted to the FDA.”
> “The new protocols, among other things, provide for the pooling of data across the ongoing U.S. and EU studies, and also prespecified the pivotal comparison of AMT-130 clinical end points compared to a propensity score-matched external control from the Enroll-HD natural history data set.”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.1-2"></a>

###### Comparison of Cohorts 1 and 2 with an Enroll-HD external control as the basis for a BLA

> “Based on interactions with the FDA, it was agreed that data from cohorts 1 and 2 in the Phase I/II studies could be compared to a propensity score-matched external control derived from the Enroll-HD natural history data set, under a prespecified statistical analysis plan, which may serve as the primary basis for a BLA submission.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.1-3"></a>

###### Updated external control comparison in the pooled protocols, September 2026

> “The new protocols, among other things, provide for the pooling of data across the ongoing U.S. and EU studies, and also prespecified the comparison of AMT-130 clinical end points compared to a propensity score-matched external control from the updated Enroll-HD natural history data set.”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Data cutoff of the three-year analysis

> “All data presented here in is as of the data cut off date of June 30, 2025, unless otherwise indicated”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.2-2"></a>

###### Data cutoff of the four-year and updated 36-month analyses

> “Today's announcement comprises results from the ongoing Phase I/II studies at two timepoints, with a data cutoff of June 30, 2026.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.2-3"></a>

###### Enroll-HD dataset releases used as external controls

> “Enroll-HD A – Release date January 2023; Enroll-HD B – Release date September 2025”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.2-4"></a>

###### Clinical trial sites of CT-AMT-130-01 and CT-AMT-130-02

| Study | Sites |
| --- | --- |
| CT-AMT-130-01 | “CT-AMT-130-01 (US)”; “University of Alabama”; “University of California, San Francisco”; “Rush University Medical Center”; “Johns Hopkins University”; “University of Michigan”; “Ohio State University”; “Vanderbilt University Medical Center”; “The University of Texas, Houston”; “Virginia Commonwealth University”; “University of Washington Medical Center”; “CenExel Rocky Mountain Clinical Research, CO”; “University of Arizona – Dept. of Neurology” |
| CT-AMT-130-02 | “CT-AMT-130-02 (UK, Poland)”; “Cardiff University”; “National Hospital for Neurology and Neurosurgery”; “Wojskowy Instytut Medycyny Lotnicze – Klinika Neurologii”; “International Neuro Center” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.2-5"></a>

###### Data cutoff of the 24-month interim analysis, July 2024

> “Across both studies, 24-month follow-up data from a total of 21 patients (n=12 low dose; n=9 high dose) were available for analysis as of a March 31, 2024 cut-off date.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.2-6"></a>

###### Data cutoff of the interim analysis, December 2023

> “The combined U.S. and European data presented in this release are subject to a September 30, 2023 cut-off date and do not include efficacy and biomarker data from the control patients who crossed over to treatment.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Prespecified statistical analysis plan of the three-year analysis

> “Prespecified statistical analysis plan was aligned with and submitted to the FDA in advance of database lock”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.3-2"></a>

###### Propensity score-matched external control reported as the prespecified primary comparison, September 2025

> “The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months compared to a propensity score-matched external control.”
> “In accordance with the prospectively defined statistical analysis plan aligned with, and submitted to, the U.S. Food and Drug Administration (FDA) for this pivotal Phase I/II study, uniQure analyzed clinical outcomes for 29 patients treated with AMT-130 (n=17 high dose; n=12 low dose) of which 12 patients per dose group had attained 36 months of follow up and were evaluated at that time point.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.3-3"></a>

###### Statistical analysis plan as described in June 2025: propensity score-weighted primary analysis planned

> “The Company plans to use propensity score-weighted external control derived from the ENROLL-HD dataset for the primary analysis and to submit certain sensitivity analyses, including one using a propensity score-matched external control, as additional support.”
> “The FDA also agreed that ENROLL-HD – a large, prospective, longitudinal, natural history study of patients with Huntington’s disease – may be acceptable as the external control dataset for the primary analysis of the trial data along with additional sensitivity analyses using the TRACK-HD/TRACK-ON and PREDICT-HD datasets.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-3.1.1.3-4"></a>

###### Enroll-HD external comparator dataset

> “Prospective data collection, largely contemporaneous with AMT-130 studies”
> “Aligns with clinical measures collected in AMT-130 studies (eg, cUHDRS, TFC, SDMT, SWRT, TMS)”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Rationale for selecting Enroll-HD

> “To date, approximately 33,000 patients have enrolled in ENROLL-HD.”
> “Compared to previously used natural history studies like TRACK-HD and PREDICT-HD, ENROLL-HD offers a substantially larger sample size, lower attrition rates, and longer average patient follow-up.”
> “The Company expects the larger sample size to reduce variability in the external control data and enhance the robustness of the SAP.”

Source: [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-3.1.1.3-6"></a>

###### Propensity score matching method and covariates

> “Primary analysis used restricted full matching with matching weights for Enroll-HD data.”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

> “Trial participants are matched to people with the most similar propensity score.”
> “Individuals with dissimilar propensity scores are excluded.”
> “(Covariates: baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, SWR)”
> “The same covariates were used in propensity score matching vs Enroll-HD, effectively mitigating potential bias arising from the absence of striatal volume data in Enroll-HD”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.3-7"></a>

###### Statistical analysis plan of the 48-month analysis with an updated external control

> “48-Month Statistical Analysis Plan Included Updated External Control”
> “Enroll-HD A: ~20,000 participants”
> “Enroll-HD B: ~26,000 participants”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.3-8"></a>

###### Propensity-weighted TRACK-HD, TRACK-ON, and PREDICT-HD external control, July 2024

> “For the first time, uniQure conducted a statistical analysis of clinical outcomes for the 21 treated patients at 24 months compared to an expanded, propensity-weighted external control (n=154) developed in collaboration with the Cure Huntington’s Disease Initiative (CHDI) using data from the TRACK-HD, TRACK-ON and PREDICT-HD natural history studies.”
> “The external control includes patients that met the Phase I/II clinical trial eligibility criteria, and whose data contributions were statistically weighted using propensity scoring to closely match the baseline characteristics of patients treated with AMT-130.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.3-9"></a>

###### Criteria-matched TRACK-HD natural history cohort, December 2023

> “Clinical and functional measurements for treated patients in each dose cohort were compared to baseline measurements, as well as to control patients (up to 12 months) and a non-concurrent criteria-matched natural history cohort.”
> “The natural history cohort was developed by uniQure in collaboration with the Cure Huntington’s Disease Initiative (CHDI) using the TRACK-HD natural history study of patients with early Huntington’s disease.”
> “The cohort includes 31 patients that met the uniQure clinical trial inclusion criteria of Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key eligibility criteria of the high-dose cohort in the three-year analysis

> “Aged 25-65 years”
> “Diagnostic confidence level: 3 or 4”
> “DCL 4, or DCL 3 if individual also meets definition of multidimensional manifest HD or has cognitive symptoms”
> “Total functional capacity: 9-13”
> “HD medications stable prior 3 months”
> “Striatal volumes exceed specified minima”
> “Putamen: ≥ 2.5 cm3/side”
> “Caudate: ≥ 2.0 cm3/side”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Selection of the Enroll-HD external control: exclusion criteria

> “Index date outside of effective enrollment window”
> “Missing baseline cUHDRS”
> “No post-baseline visit within Year 1, Year 2, or Year 3 visit windows”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Single administration into the striatum

> “One-time administration via MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen)”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.5-2"></a>

###### Treated participants by dose and imitation surgery controls, July 2024

> “A total of 29 patients received one of two doses of AMT-130 (n=12 low dose; n=17 high dose) and 10 control patients received imitation surgery.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using cUHDRS Change at 36 Months as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary, secondary, and supportive endpoints of the three-year analysis

| Endpoint role | Measure |
| --- | --- |
| Primary endpoint | “Composite Unified Huntington’s Disease Rating Scale (cUHDRS)”; “Change from baseline at 36-months vs Enroll-HD propensity score-matched external control” |
| Secondary endpoints | “Total Functional Capacity (TFC)”; “Symbol Digit Modalities Test (SDMT)”; “Stroop Word Reading Test (SWRT)”; “Total Motor Score (TMS)” |
| Supportive endpoint | “Cerebrospinal fluid (CSF) Neurofilament light chain (NfL) change from baseline at 36-months” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint of the 48-month analysis

> “Change from baseline at 48-months vs Enroll-HD B propensity score-matched external control”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.6.1-3"></a>

###### Components of the cUHDRS as described by the sponsor

| Component | Domain described |
| --- | --- |
| Total Functional Capacity (TFC) | “Impairments in occupation, finance, domestic chores, daily living, and care level” |
| Total Motor Score (TMS) | “Impairment in motor function” |
| Symbol Digit Modalities Test (SDMT) | “Measure of attention, processing speed, and working memory” |
| Stroop Word Reading Test (SWRT) | “Measure of selective attention capacity and processing speed” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.6.1-4"></a>

###### Regulatory acceptance of cUHDRS as an intermediate clinical endpoint, December 2024

> “FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

<a id="topic-3.1.1.6.1-5"></a>

###### Sponsor statement on the sensitivity of the cUHDRS

> “cUHDRS has been demonstrated to be the most sensitive measurement of clinical progression in Huntington’s disease patients”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.6.1-6"></a>

###### Derivation of the cUHDRS from four UHDRS measures

> “The overall pattern of the correlations and the PCA results indicated that TMS, TFC, SDMT, and SWR had significant overlap, but PBA-apathy did not.”
> “Note the negative sign for (scaled) TMS and the positive sign for all other variables.”
> “The observed difference in the S/N ratio between the cUHDRS and each individual component in TRACK-HD was numerically superior in all cases (e.g., 26%–38% larger than the best individual measure, which was the TMS at 24 and 36 months, respectively)”
> “The results (ICC2,1 = 0.96)9 showed excellent test-retest reliability of the cUHDRS.”

Source: [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)

<a id="topic-3.1.1.6.1-7"></a>

###### Clinically efficacious slowing on the cUHDRS

> “We have reached consensus that a slowing of clinical decline in the range of 20% to 30% annually on the cUHDRS (≈0.2–0.3 points per year), equivalent to ≈2.4 to 3.5 mo/y of time saved from progression, can be used to define a clinically efficacious treatment in this setting.”

Source: [Schobel et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5729794/)

<a id="topic-3.1.1.6.1-8"></a>

###### Correlation of the cUHDRS with imaging biomarkers

> “Worse performance in the cUHDRS over time correlated with longitudinal volume decreases in the occipito-parietal cortex and centrum semiovale, whereas lower baseline scores correlated with decreased volume in the basal ganglia and surrounding WM.”
> “The cUHDRS correlates with imaging biomarkers and tracks atrophy progression in HD supporting its biological relevance.”

Source: [Estevez-Fraga et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33471951/)

<a id="topic-3.1.1.6.1-9"></a>

###### Key secondary endpoint: Total Functional Capacity

> “It assesses capacity as opposed to actual performance and consists of a 5‐item interview between a clinician, and the patient and a person familiar with the patient's functioning.”
> “Extensive data from multiple observational studies and clinical trials suggest sensitivity to change over time.”
> “There appears to be a ceiling effect for early stage HD and a floor effect for late stage HD.”
> “Recommendation: The UHDRS‐TFC is suggested for assessing severity of limitation in functional capacity in HD, because it lacks core clinimetric data, namely, test–retest reliability and internal consistency to reach a “recommended” status.”

Source: [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)

<a id="topic-3.1.1.6.1-10"></a>

###### Total Functional Capacity as a measure of daily function: investigator statement

> “Total Functional Capacity tracks things that matter the most to patients and families – ability to work, perform household chores and handle daily self-care activities.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.6.1-11"></a>

###### Secondary endpoints: Symbol Digit Modalities Test and Stroop Word Reading Test

> “(1) the symbol digit modalities test (SDMT/sampled cognitive domains: visual attention, working memory, symbolic encoding, and psychomotor speed), in which the total score corresponds to the number of correct responses within 90 seconds”
> “(2) the Stroop color word interference test (sampled cognitive domains: psychomotor speed, cognitive flexibility, response inhibition, and selective attention), which includes 3 conditions (word reading, color naming, interference), each one of which is scored as the total number of items accurately completed within 45 seconds”

Source: [Mestre et al. (2018a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10080408/)

<a id="topic-3.1.1.6.1-12"></a>

###### Supportive endpoint: cerebrospinal fluid neurofilament light chain

> “CSF NfL is a well-characterized, supportive biomarker of neurodegeneration. Elevation in CSF NfL has been shown to be strongly associated with greater clinical severity of Huntington’s disease.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

> “Recent data from HD-CSF study where CSF NfL levels were measured in 71 patients over a two-year period showed an increase over time and a sigmoid trajectory with age.”
> “The study demonstrated early-manifest HD patients will experience increases in CSF NfL of ~10% to 15% per year”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.6.1-13"></a>

###### Natural history of cerebrospinal fluid neurofilament light chain in the HD-CSF cohort

> “mHTT in CSF, as well as NfL in CSF and plasma, all rose detectably within participants over 2 years.”
> “On the basis of simulations of the models in Fig. 2 (D to F), CSF NfL rose in manifest HD by 98.85 pg/ml per year, in preHD by 79.16 pg/ml per year, and in controls by 20.05 pg/ml per year (Fig. 2J).”

Source: [Rodrigues et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7611886/)

<a id="topic-3.1.1.6.1-14"></a>

###### Natural history comparator for cerebrospinal fluid neurofilament light chain, July 2024

> “An independent natural history study demonstrated a 26% increase in CSF NfL at 24 months in patients with early manifest Huntington’s disease (n=19).”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Participants and external controls in the three-year analysis

> “Outcomes for each dose group were compared to a propensity score-matched external control drawn from the Enroll-HD natural history data set (n=940 for high dose; n=626 for low dose).”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.7.1-2"></a>

###### Participants with data at each visit in the three-year analysis, high dose

| Group and endpoint | Baseline | 12 months | 24 months | 36 months |
| --- | --- | --- | --- | --- |
| AMT-130 high dose (cUHDRS and TFC) | “17” | “17” | “15” | “12” |
| PSM external control, cUHDRS | “940” | “715” | “586” | “568” |
| PSM external control, TFC | “940” | “725” | “597” | “583” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants and external controls in the four-year and updated 36-month analyses

> “Twenty-nine patients have been treated with ifezuntirgene inilparvovec (n=17 high dose; n=12 low dose) across the studies’ first two cohorts. The new 36-month analysis now includes 15 high-dose and 12 low-dose patients, with three additional high-dose patients having reached that timepoint since the September 2025 analysis.”
> “The 48-month analysis includes 12 patients at each dose.”
> “Outcomes for the 36-month and 48-month analyses were compared to propensity score-matched external controls (n=1,337 for high dose) from an updated ENROLL-HD natural history dataset with a September 2025 cutoff.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants with data at each visit in the four-year analysis, high dose

| Group and endpoint | Baseline | 12 months | 24 months | 36 months | 48 months |
| --- | --- | --- | --- | --- | --- |
| AMT-130 high dose (cUHDRS and TFC) | “17” | “17” | “15” | “15” | “12” |
| Enroll-HD B, cUHDRS | “1337” | “953” | “760” | “690” | “625” |
| Enroll-HD B, TFC | “1337” | “967” | “772” | “704” | “641” |
| Enroll-HD A, cUHDRS (post hoc) | “619” | “484” | “398” | “355” | “349” |
| Enroll-HD A, TFC (post hoc) | “619” | “492” | “401” | “360” | “364” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.7.1-5"></a>

###### Participants with cerebrospinal fluid neurofilament light chain samples, through 48 months

| Dose | Base | 1M | 3M | 6M | 9M | 12M | 15M | 18M | 24M | 30M | 36M | 48M |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| High-Dose | “17” | “17” | “16” | “16” | “15” | “14” | “14” | “15” | “15” | “14” | “14” | “11” |
| Low-Dose | “12” | “12” | “11” | “12” | “12” | “12” | “12” | “12” | “12” | “12” | “12” | “11” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.7.1-6"></a>

###### Participants in the 24-month interim analysis, July 2024

> “uniQure is conducting two multi-center Phase I/II clinical trials of AMT-130 in the U.S. (n=26) and Europe/UK (n=13).”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.7.1-7"></a>

###### Participants in the interim analysis, December 2023

> “today announced updated interim data including up to 30 months of follow-up from 39 patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington’s disease.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Derivation of the Enroll-HD external control arm analysis set

| Step | Participants |
| --- | --- |
| Diagnosis of HD in ENROLL-HD | “N = 19,542” |
| Met AMT-130 eligibility criteria | “N = 6,596 (33.8%)” |
| Did not meet AMT-130 eligibility criteria | “N = 12,946” |
| Excluded from the analysis set | “N = 3,326” |
| External control arm analysis set | “N = 3,270 (49.6%)” |
| Propensity-score matched to High-Dose cohort | “N = 940” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Analysis method for the primary and key secondary endpoints

> “LSM change from baseline at 3 years (±SE; MMRM)”
> “Above graph represents weighted observed data”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Primary and post hoc comparisons in the 48-month analysis

> “Primary Analysis (compared to Enroll-HD B)”
> “Post Hoc Analysis (compared to Enroll-HD A)”
> “48-Month Completers Only (n=12)”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Safety analysis set and adverse event definitions, June 2025 data cutoff

> “TEAEs are defined as AEs after Day 0.”
> “Perioperative AEs had onset Day 0 to 13. Safety data as of June 30, 2025; &1 low dose and 3 high dose cross-over patients included”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Follow-up at the three-year data cutoff

> “n = 12 had 3 years of follow-up as of June 30, 2025”
> “n = 583 from Enroll-HD had 3 years of post-eligibility follow-up”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Lumbar puncture declined at 36 months

> “1 of 12 patients declined to undergo a lumbar puncture procedure”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic and baseline characteristics of the high-dose cohort and the propensity score-matched external control

| Characteristic, mean (SD) | AMT-130 high dose (N=17) | PSM external control, Enroll-HD (N=940) |
| --- | --- | --- |
| Sex, males (%) | “47.1” | “55.6” |
| Age | “45.8” | “45.2” |
| CAG repeats | “42.4” | “42.8” |
| CAP100 score | “86.2” | “86.8” |
| DCL = 3, 4 (%) | “35.3, 64.7” | “30.5, 69.5” |
| PIN score | “0.77” | “0.81” |
| cUHDRS | “14.9” | “14.7” |
| TFC | “12.2” | “12.1” |
| SDMT | “46.1” | “45.3” |
| SWRT | “89.9” | “87.6” |
| TMS | “12.1” | “11.6” |
| HD-ISS Stage 2, 3 (%) | “47.1, 52.9” | “51.6, 48.4” |
| Region; No. America, Other (%) | “58.8, 41.2” | “28.9, 71.1” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Sponsor assessment of baseline balance

> “The propensity score-matched external control has well-matched baseline characteristics to the patients treated with high-dose AMT-130.”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Baseline scores of the treated cohorts, December 2023

> “composite Unified Huntington’s Disease Rating Scale (cUHDRS): AMT-130 showed a favorable difference in cUHDRS of 0.39 points at 30 months and 1.24 points at 18 months for the low- and high-dose, respectively (baseline values: 14.1 in low-dose and 14.9 in high-dose).”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint at 36 months: cUHDRS, high dose

> “A statistically significant 75% slowing of disease progression as measured by cUHDRS (p=0.003), which met the primary endpoint of the study. Treated patients had a mean change in cUHDRS from baseline of -0.38 compared to a change of -1.52 for patients in the propensity score-matched external control.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-2"></a>

###### Key secondary endpoint at 36 months: TFC, high dose

> “A statistically significant 60% slowing of disease progression as measured by TFC (p=0.033), which met a key secondary endpoint of the study. Treated patients had a mean change in TFC from baseline of -0.36 compared to a change of -0.88 for patients in the propensity score-matched external control.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-3"></a>

###### Other secondary endpoints at 36 months: SDMT, high dose

> “Favorable trends in other secondary endpoint measures of motor and cognitive function, including Symbol Digit Modalities Test (SDMT), Stroop Word Reading Test (SWRT) and Total Motor Score (TMS).”
> “An 88% slowing of disease progression as measured by SDMT (p=0.057), with a mean change in SDMT from baseline of -0.44 compared to a change of -3.73 for patients in the propensity score-matched external control.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-4"></a>

###### Other secondary endpoints at 36 months: SWRT and TMS, high dose

> “A 113% slowing of disease progression as measured by SWRT (nominal p=0.002), with a mean change in SWRT from baseline of 0.88 compared to a change of -6.98 for patients in the propensity score-matched external control.”
> “A 59% slowing of disease progression as measured by TMS (nominal p=0.174), with a mean change in TMS from baseline of 2.01 compared to a change of 4.88 for patients in the propensity score-matched external control.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.1.8.3-5"></a>

###### Results at 36 months, low dose

| Endpoint | AMT-130 low dose (N=12), LSM change (SE) | Enroll-HD PSM external control, LSM change (SE) | External control N | LSM difference [95% CI] | Slowing of disease progression (%) | P-value |
| --- | --- | --- | --- | --- | --- | --- |
| cUHDRS | “-1.65 (0.411)” | “-1.72 (0.151)” | “N=383” | “0.07  [-0.75, 0.88]” | “3.9” | “0.871” |
| TFC | “-0.33 (0.296)” | “-1.04 (0.120)” | “N=392” | “0.71  [0.12, 1.31]” | “68.1” | “0.019” |
| SDMT | “-6.44 (1.532)” | “-3.35 (0.503)” | “N=387” | “-3.09  [-6.14, -0.05]” | “-92.3” | “0.046” |
| SWRT | “-3.67 (4.134)” | “-5.20 (1.373)” | “N=387” | “1.44 [-7.45, 10.33]” | “27.7” | “0.751” |
| TMS | “8.64 (2.039)” | “5.61 (0.688)” | “N=392” | “3.02 [-1.23, 7.28]” | “-53.9” | “0.163” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

> “P-value is nominal; hierarchical testing was discontinued for p-value >0.05”
> “Patients receiving low-dose AMT-130 showed variable trends in functional, motor and cognitive endpoints, suggestive of a dose-dependent effect”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.3-6"></a>

###### Dose response and sensitivity analyses at 36 months

> “The Company believes that the consistently favorable results in functional, motor and cognitive endpoints at 36 months observed in the high dose group, compared to the variable trends observed in the low dose group, reflect a dose-dependent response to AMT-130.”
> “Various other supportive analyses of the results from the AMT-130 high dose treatment group, including those using a propensity score-weighted external control and comparisons to the TRACK-HD and PREDICT-HD datasets, were consistent with the primary analysis.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.3-7"></a>

###### Supportive endpoint at 36 months: cerebrospinal fluid neurofilament light chain

> “A mean reduction from baseline in cerebrospinal neurofilament light protein (CSF NfL) of -8.2%.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

| Group | Participants | Change in mean CSF NfL from baseline (%) |
| --- | --- | --- |
| AMT-130 high dose | “N=11” | “- 8.2” |
| AMT-130 low dose | “N=12” | “- 4.7” |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.3-8"></a>

###### Cerebrospinal fluid neurofilament light chain at 2 and 3 years, high dose

| Timepoint | Participants | CSF NfL mean change from baseline |
| --- | --- | --- |
| Year 2 | “N = 15” | “-9.7%” |
| Year 3 | “N = 11” | “-8.2%” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.8.3-9"></a>

###### Updated 36-month analysis: cUHDRS and TFC, high dose (n=15)

> “cUHDRS showed 80% slowing of disease progression compared to the updated external control (nominal p=0.005). Treated patients had a mean change in cUHDRS from baseline of -0.28 compared to a change of -1.39 for the external control, a favorable treatment difference of 1.12 compared to baseline.”
> “TFC showed 67% slowing of disease progression compared to the updated external control (nominal p=0.011). Treated patients had a mean change in TFC from baseline of -0.27 compared to a change of -0.82 for patients in the propensity score-matched external control, a favorable treatment difference of 0.55 compared to baseline.”
> “Mean cerebrospinal neurofilament light protein (CSF NfL) was 6% below baseline (n=14).”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.3-10"></a>

###### Updated 36-month analysis: other secondary endpoints, high dose

| Endpoint | AMT-130 high dose (N=17), LSM change | Enroll-HD B (N=1337), LSM change | Slowing of disease progression | P-value |
| --- | --- | --- | --- | --- |
| SDMT | “0.67” | “-2.78” | “Slowed HD progression by 124% based on SDMT” | “p=0.040” |
| SWRT | “1.32” | “-5.75” | “Slowed HD progression by 123% based on SWRT” | “p=0.047” |
| TMS | “1.93” | “4.77” | “Slowed HD progression by 59% based on TMS” | “p=0.114” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

> “p-values are nominal”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-11"></a>

###### Primary analysis at 48 months: cUHDRS and TFC, high dose (n=12)

> “cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Treated patients had a mean change in cUHDRS from baseline of -0.90 compared to a change of -1.61 for the external control, a favorable treatment difference of 0.71 compared to baseline.”
> “TFC showed 61% slowing of disease progression compared to the updated external control (nominal p=0.008). Treated patients had a mean change in TFC from baseline of -0.37 compared to a change of -0.94 for the external control, a favorable treatment difference of 0.57 compared to baseline.”
> “Mean cerebrospinal neurofilament light protein (CSF NfL) was 4% above baseline (n=11).”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.3-12"></a>

###### Primary analysis at 48 months: other secondary endpoints, high dose

| Endpoint | AMT-130 high dose (N=12), LSM change | Enroll-HD B, LSM change | Enroll-HD B N | Slowing of disease progression | P-value |
| --- | --- | --- | --- | --- | --- |
| SDMT | “-2.75” | “-3.43” | “Enroll-HD B (N=634)” | “Slowed HD progression by 20% based on SDMT” | “p=0.731” |
| SWRT | “0.95” | “-7.53” | “Enroll-HD B (N=633)” | “Slowed HD progression by 113% based on SWRT” | “p=0.006” |
| TMS | “4.82” | “5.10” | “Enroll-HD B (N=631)” | “Slowed HD progression by 5.6% based on TMS” | “p=0.908” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-13"></a>

###### Post hoc analysis at 48 months against the prior Enroll-HD external control

> “In a post-hoc sensitivity analysis using the prior ENROLL-HD external control, the 48-month analysis showed 53.5% slowing based on cUHDRS (nominal p=0.041) and 68.3% based on TFC (nominal p=0.001).”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

| Endpoint | AMT-130 high dose (N=17), LSM change | Enroll-HD A (N=619), LSM change | Slowing of disease progression |
| --- | --- | --- | --- |
| cUHDRS | “-0.90” | “-1.94” | “54% slowing of disease progression at 48 months (p=0.041” |
| TFC | “-0.39” | “-1.24” | “68% slowing of disease progression at 48 months (p<0.001” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-14"></a>

###### Dose comparison at 48 months

> “The observed differences between the high and low doses are consistent with a dose-dependent treatment effect. At 48 months, mean change from baseline in cUHDRS was –0.91 in high-dose patients compared with −1.94 in low-dose patients, a difference of 1.03 in favor of the high dose. Mean change from baseline in TFC was −0.30 in high-dose patients compared with −0.70 in low-dose patients, a difference of 0.40 in favor of the high dose.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.3-15"></a>

###### Cerebrospinal fluid neurofilament light chain through 48 months, both doses

> “CSF NfL levels maintained near baseline starting from Month 18 and up to 4 years”
> “Mean CSF NfL was 4% above baseline for the high-dose and 8% below baseline for the low-dose at Month 48”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.3-16"></a>

###### Interim results at 24 months against the propensity-weighted external control, July 2024

> “At 24 months, the mean change in cUHDRS for patients receiving the high-dose of AMT-130 was -0.2 compared to -1.0 for patients in the propensity score-weighted external control, representing an 80% slowing of disease progression (p=0.007).”
> “At 24 months, the mean change in cUDHRS for patients receiving the low-dose of AMT-130 was -0.7 compared to -1.0 for patients in the propensity score-weighted external control, representing a 30% slowing of disease progression (p=0.21).”
> “Patients treated with AMT-130 had a mean reduction in CSF NfL of 11% compared to baseline (p=0.02) at 24 months.”
> “Mean CSF NfL levels for both high and low doses were below baseline at 24 months.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.8.3-17"></a>

###### Interim results against the criteria-matched TRACK-HD cohort, December 2023

> “Total Functional Capacity (TFC): AMT-130 showed a favorable difference in TFC of 0.95 points at 30 months in the low-dose and 0.49 points at 18 months in the high-dose (baseline values: 11.9 in low-dose and 12.2 in high-dose).”
> “Total Motor Score (TMS): AMT-130 showed a favorable difference in TMS of 2.80 points at 30 months in the low-dose and 1.70 points in the high-dose at 18 months (baseline values: 13.3 in low-dose and 12.1 in high-dose).”
> “Neurofilament Light Chain (NfL): Mean CSF NfL for the low-dose cohort remained below baseline through month 30 and was 6.6% below baseline. Mean CSF NfL for the high-dose cohort also further declined and is near baseline at month 18.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Safety summary at the three-year data cutoff

> “AMT-130 was generally well-tolerated, with a manageable safety profile at both doses. As of June 30, 2025, no new drug-related serious adverse events have been observed since December 2022. The most common adverse events in the treatment groups were related to the administration procedure, which all resolved.”

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii)

<a id="topic-3.1.1.8.5-2"></a>

###### Timing and resolution of drug-related serious adverse events

> “The majority of drug-related serious adverse events occurred within the first weeks post treatment and fully resolved with steroids or supportive care”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Adverse events in Cohorts 1 to 3, June 2025 data cutoff

| Adverse event, N (%) | Sham surgery (n=10) | Low-dose AMT-130, Cohort 1 (n=13) | High-dose AMT-130, Cohort 2 (n=20) | Dose-blinded, Cohort 3 (n=12) | All AMT-130, Cohorts 1, 2 and 3 (n=45) |
| --- | --- | --- | --- | --- | --- |
| Any TEAEs | “10” (“100.0”) | “12” (“92.3”) | “20” (“100.0”) | “12” (“100”) | “44” (“97.8”) |
| Any SAEs | “1” (“10.0”) | “3” (“23.1”) | “9” (“45.0”) | “3” (“25”) | “15” (“33.3”) |
| Any SAEs (peri-operative) | “1” (“10.0”) | “2” (“15.4”) | “6” (“30.0”) | “0” (“0.0”) | “8” (“17.8”) |
| Any drug-related TEAE | “0” (“0.0”) | “0” (“0.0”) | “6” (“30.0”) | “3” (“25.0”) | “9” (“20.0”) |
| Any drug-related SAE | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “0” (“0.0”) | “4” (“8.8”) |
| Headache | “3” (“30.0”) | “3” (“23.1”) | “9” (“45.0”) | “6” (“50.0”) | “18” (“40.0”) |
| Procedural headache | “5” (“50.0”) | “4” (“30.8”) | “10” (“50.0”) | “2” (“16.7”) | “16” (“35.6”) |
| Procedural pain | “6” (“60.0”) | “2” (“15.4”) | “7” (“35.0”) | “2” (“16.7”) | “11” (“24.4”) |
| Post lumbar puncture syndrome | “6” (“60.0”) | “2” (“15.4”) | “5” (“25.0”) | “2” (“16.7”) | “10” (“22.2”) |
| Procedural complication | “4” (“40.0”) | “4” (“30.8”) | “5” (“25.0”) | “0” (“0.0”) | “9” (“20.0”) |
| Anxiety | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “4” (“33.3”) | “8” (“17.8”) |
| Constipation | “0” (“0.0”) | “0” (“0.0”) | “2” (“10.0”) | “6” (“50.0”) | “8” (“17.8”) |
| Insomnia | “0” (“0.0”) | “1” (“7.7”) | “1” (“5.0”) | “6” (“50.0”) | “8” (“17.8”) |
| Back pain | “1” (“10.0”) | “0” (“0.0”) | “0” (“0.0”) | “5” (“41.7”) | “5” (“11.1”) |

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-3.1.1.8.5-4"></a>

###### Reclassified serious adverse event and most common adverse events, June 2025 data cutoff

> “One SAE reported as “tension headache” was retrospectively considered by uniQure as a case of CNS inflammation.”
> “Most common AEs (≥20%): Headache, procedural pain, post-lumbar puncture syndrome”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.8.5-5"></a>

###### Safety summary at the four-year data cutoff

> “Ifezuntirgene inilparvovec continues to be generally well-tolerated, with a manageable safety profile at both doses. The most common adverse events in the treatment groups were related to the administration procedure, and all have resolved. As previously disclosed, five high dose participants (17%) experienced a treatment-related serious adverse event (SAE) related to central nervous system inflammation, all of which fully resolved.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

> “No new treatment-related serious adverse events (SAE) reported in Cohorts 1 and 2”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Suicide in a low-dose participant

> “Since the September 2025 data readout, one suicide in a low-dose patient occurred, approximately five years after receiving treatment. This was assessed as unrelated to treatment by the study investigator.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

<a id="topic-3.1.1.8.5-7"></a>

###### Adverse events in all 51 treated participants, June 2026 data cutoff

| Adverse event, N (%) | Sham surgery (n=10) | Low-dose AMT-130, Cohort 1 (n=13) | High-dose AMT-130, Cohort 2 (n=20) | Dose-blinded AMT-130, Cohort 3 (n=12) | High-dose AMT-130, Cohort 4 (n=6) | All AMT-130, Cohorts 1, 2, 3 and 4 (n=51) |
| --- | --- | --- | --- | --- | --- | --- |
| Any TEAEs | “10” (“100.0”) | “12” (“92.3”) | “20” (“100.0”) | “12” (“100”) | “6” (“100”) | “50” (“98”) |
| Any SAEs | “1” (“10.0”) | “4” (“30.8”) | “10” (“50.0”) | “4” (“33.3”) | “2” (“33”) | “20” (“39.2”) |
| Any SAEs (peri-operative) | “1” (“10.0”) | “2” (“15.4”) | “6” (“30.0”) | “0” (“0.0”) | “1” (“16.7”) | “9” (“17.6”) |
| Any drug-related TEAE | “0” (“0.0”) | “0” (“0.0”) | “6” (“30.0”) | “3” (“25.0”) | “2” (“33.3”) | “11” (“21.5”) |
| Any drug-related SAE | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “0” (“0.0”) | “1” (“16.7”) | “5” (“9.80”) |
| Headache | “3” (“30.0”) | “2” (“15.4”) | “9” (“45.0”) | “6” (“50.0”) | “4” (“66.7”) | “21” (“41.2”) |
| Procedural headache | “5” (“50.0”) | “4” (“30.8”) | “10” (“50.0”) | “2” (“16.7”) | “0” (“0.0”) | “16” (“31.4”) |
| Procedural pain | “6” (“60.0”) | “2” (“15.4”) | “7” (“35.0”) | “3” (“25.0”) | “1” (“16.7”) | “13” (“25.5”) |
| Post lumbar puncture syndrome | “6” (“60.0”) | “2” (“15.4”) | “6” (“30.0”) | “2” (“16.7”) | “0” (“0.0”) | “10” (“19.6”) |
| Procedural complication | “4” (“40.0”) | “3” (“23.1”) | “4” (“20.0”) | “0” (“0.0”) | “0” (“0.0”) | “7” (“13.7”) |
| Anxiety | “0” (“0.0”) | “0” (“0.0”) | “4” (“20.0”) | “4” (“33.3”) | “3” (“50.0”) | “11” (“21.6”) |
| Constipation | “0” (“0.0”) | “0” (“0.0”) | “2” (“10.0”) | “6” (“50.0”) | “1” (“16.7”) | “9” (“17.6”) |
| Insomnia | “0” (“0.0”) | “1” (“7.7”) | “1” (“5.0”) | “6” (“50.0”) | “2” (“33.3”) | “10” (“19.6”) |
| Back pain | “1” (“10.0”) | “0” (“0.0”) | “0” (“0.0”) | “5” (“41.7”) | “0” (“0.0”) | “5” (“9.8”) |
| Procedural nausea | “0” (“0.0”) | “3” (“23.1”) | “3” (“15.0”) | “1” (“8.3”) | “2” (“33.3”) | “9” (“17.6”) |
| Paraesthesia | “1” (“10.0”) | “0” (“0.0”) | “1” (“5.0”) | “1” (“8.3”) | “2” (“33.3”) | “4” (“7.8”) |
| Sleep disorder | “0” (“0.0”) | “0” (“0.0”) | “0” (“0.0”) | “4” (“33.3”) | “0” (“0.0”) | “4” (“7.8”) |
| Sensory loss | “0” (“0.0”) | “0” (“0.0”) | “0” (“0.0”) | “1” (“8.3”) | “2” (“33.3”) | “3” (“5.9”) |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

> “TEAEs are defined as AEs on or after Day 0.”
> “Safety data as of June 30, 2026; * 1 low dose and 3 high dose cross-over patients included”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.8.5-8"></a>

###### Safety at the 24-month interim analysis, July 2024

> “Based on data observed to date, AMT-130 remains generally well-tolerated, with a manageable safety profile at both doses. There were no new AMT-130-related serious adverse events reported.”

Source: [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating)

<a id="topic-3.1.1.8.5-9"></a>

###### Serious adverse events across both studies, December 2023

> “There were four serious adverse events (SAE) unrelated to AMT-130 (post-operative delirium, major depression, suicidal ideation and epistaxis) in the low-dose cohort, six unrelated SAEs in the high-dose cohort (back pain, hypothermia, post procedural hematoma, post-lumbar puncture syndrome (n=2), pulmonary embolism), and one SAE (deep vein thrombosis) in the control group.”
> “In addition, there were four AMT-130-related serious adverse events in the high-dose cohort (central nervous system inflammation (n=3), and severe headache (1) that, retrospectively, also was attributable to central nervous system inflammation.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- External comparison: efficacy is assessed against a propensity score-matched external control from the Enroll-HD natural history data set. The Form 10-K states that the analyses rely on external historical controls and that these may not be accepted as a basis for regulatory approval. After a Type A meeting in January 2026, the FDA stated that it cannot agree that these data are sufficient as primary evidence of effectiveness. One commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”.
- Open-label treatment: the same commentary noted that most participants were in open-label arms, so a placebo effect is possible. An analysis of the GENERATION HD1 placebo arm found a placebo response on the cognitive scores (SDMT and SWR), which also influences the cUHDRS.
- Matching covariates: MRI data were not collected in Enroll-HD, so striatal volume, a predictor of decline and an eligibility criterion of the phase I/II studies, could not be matched. The sponsor analysis used baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR and reports that other covariates can substitute for striatal volume. A comment submitted to ICER listed limits of the natural history comparison, including bias from selection into a surgical trial versus a registry, different visit schedules, and very small numbers of treated patients at longer follow-up.
- Small numbers: 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; CSF NfL was available for 11 high-dose participants at 36 months in the three-year analysis.
- Missing data and changes in the control: missingness in the updated Enroll-HD matched controls reached 53% at 48 months, controls with longer follow-up declined more slowly, and decline in Enroll-HD B was 20% slower than in Enroll-HD A at 48 months. Against Enroll-HD B the 48-month cUHDRS result did not reach statistical significance (p=0.144); the result against Enroll-HD A comes from a post-hoc sensitivity analysis. A news report on the four-year analysis noted that the natural history database is updated, which “can alter results”.
- Analysis choices and nominal p-values: the June 2025 release described a propensity score-weighted primary analysis, while the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis. The 24-month comparison with a propensity-weighted external control of 154 participants was a post-hoc analysis. Several p-values are nominal, which the Form 10-K states regulators may weigh less than standard p-values.
- Reporting: the results are reported in company press releases, presentations, and SEC filings. One commentary noted that individual data points are not shown, error bars are not defined, data from imitation (sham) procedure participants are not shown, and there are no data on mutant HTT lowering.

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2); [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/); [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/); [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease)

<a id="topic-3.1.1.9-2"></a>

###### Sponsor-disclosed risks of external controls, post hoc analyses, and nominal p-values

> “For example, in conjunction with our July 2024 interim data update for AMT-130, we conducted a post-hoc analysis of clinical outcomes for the 21 treated patients at 24 months compared to an expanded, propensity-weighted external control consisting of 154 patients.”
> “In addition, analyses of our clinical trial data may, and do, rely on external historical controls, rather than blinded, placebo-controlled comparator populations, which may not be accepted as a basis for regulatory approval.”
> “Nominal p-values are subject to certain limitations, and because of these limitations, regulatory authorities may give less weight to nominal p-values, compared to standard p-values.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.1.9-3"></a>

###### Missing data and survivor bias in the updated Enroll-HD external control

> “As is common with longitudinal natural history studies, missingness of data increased with duration of follow-up, reaching 53% in the updated ENROLL-HD matched controls at 48 months. The Company’s analysis of the updated control showed that patients discontinuing follow-up were progressing materially faster than those remaining in the control group. The Company believes these factors likely understated disease progression in the control and the resulting treatment effect of ifezuntirgene inilparvovec at 48 months.”

Source: [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies)

| Enroll-HD B participants, by last available data | Annualized cUHDRS change from baseline |
| --- | --- |
| Participants with last data at Y1 | “-0.91” |
| Participants with last data at Y2 | “-0.82” |
| Participants with last data at Y3 | “-0.73” |
| Participants with last data at Y4 or more | “-0.41” |

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

> “Participants with longer follow up declined more slowly, enriching the comparator with slower progressors”
> “Data missingness in Enroll-HD B reached 53% at Month 48”
> “These effects were more evident in Enroll-HD B than in Enroll-HD A”
> “At 48 months, Enroll-HD B decline was 20% slower than Enroll-HD A”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-3.1.1.9-4"></a>

###### Absence of striatal volume data in Enroll-HD

> “MRI data were not collected as part of Enroll-HD protocol”
> “Without correction for other baseline characteristics, participants with high striatal volume tended to have slower clinical and MRI progression”
> “Previous studies have indicated that striatal volume is predictive of decline, this was replicated in the TRACK-HD/TRACK-ON/PREDICT-HD combined cohort”
> “However, propensity score analysis supported that other covariates can be substituted to adjust for the effect of striatal volume on cUHDRS & TFC outcomes”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.9-5"></a>

###### Effect of volumetric criteria on 3-year decline in TRACK-HD, TRACK-ON, and PREDICT-HD

| Analysis | Volumetric criteria applied (N = 232) | Volumetric criteria not applied (N = 442) |
| --- | --- | --- |
| cUHDRS mean change from baseline to 3 years, unweighted | “-1.4” | “-1.7” |
| cUHDRS mean change from baseline to 3 years, PS weighted | “-1.4” | “-1.4” |
| TFC mean change from baseline to 3 years, unweighted | “-1.0” | “-1.2” |
| TFC mean change from baseline to 3 years, PS weighted | “-0.9” | “-0.9” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

> “Baseline Volumetric Criteria Are No Longer Predictive of cUHDRS Decline When Propensity Score Adjustments Are Applied”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-3.1.1.9-6"></a>

###### Independent commentary on the external control comparison, October 2025

> “As you can appreciate, the evidence of efficacy here depends entirely on the ENROLL-HD controls being well-matched.”
> “Most of the patients in the Uniqure trial were in open label arms, so there could be some placebo effect, perhaps mediated by belief in the therapy and greater effort to do well on the tests.”
> “Individual data points are not shown in any of the plots; error bars are shown but never defined.”
> “The data from imitation/sham procedure patients are not shown and their absence is not explained.”
> “There are no data on target engagement (mutant HTT lowering), which would greatly inform our prior for whether the therapy worked.”

Source: [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/)

<a id="topic-3.1.1.9-7"></a>

###### Analyst commentary on the four-year analysis, September 2026

> “One is the natural history database, which presents some challenges. Not only does the database get updated, which can alter results, but more information can go missing the longer patients are followed.”

Source: [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/)

<a id="heading-3.1.2"></a>

#### 3.1.2 CT-AMT-130-01

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Safety and proof of concept in a first-in-human study

> “This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC).”
> “Cohort 4 will further evaluate the safety of high dose AMT-130 in participants with low striatal volume.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.1-2"></a>

###### Objective described in March 2022

> “The ongoing Phase I/II clinical trial of AMT-130 is a randomized, sham controlled, double-blinded study to explore the safety, tolerability, and proof of concept of AMT-130 in patients with early manifest Huntington’s disease.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### United States study sites in the registry record

| Site | City |
| --- | --- |
| University of Alabama at Birmingham | “Birmingham” |
| University of Arizona (Surgical Site Only) | “Tucson” |
| University of California, San Francisco | “San Francisco” |
| CenExel Rocky Mountain Clinical Research | “Englewood” |
| Rush University Medical Center | “Chicago” |
| Johns Hopkins University | “Baltimore” |
| University of Michigan Department of Neurology | “Ann Arbor” |
| Ohio State University | “Columbus” |
| Vanderbilt University Medical Center | “Nashville” |
| The University of Texas | “Houston” |
| Virginia Commonwealth University VCU School of Medicine, Department of Neurology | “Richmond” |
| University of Washington Medical Center | “Seattle” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.2-2"></a>

###### Study dates in the registry record

| Date | Registry value |
| --- | --- |
| Study start (actual) | “2019-09-06” |
| Primary completion (estimated) | “2029-06” |
| Study completion (estimated) | “2029-12” |
| Last update posted | “2025-10-21” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.2-3"></a>

###### First participants treated in the United States, June 2020

> “today announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease have been treated.”
> “The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States, with now one patient treated with AMT-130, and one patient who received the imitation surgery.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.2-4"></a>

###### Study dates in the original registry record, October 2019, superseded

| Field | Registry value |
| --- | --- |
| Version | “Viewing V1 (2019-10-07)” |
| Study start | “2019-10 [Estimated]” |
| Primary completion | “2022-12 [Estimated]” |
| Study completion | “2026-05 [Estimated]” |

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Design in the current registry record

> “A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease”
> “CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) study.”
> “The first three cohorts of the study have completed enrollment, including the randomized, double-blind, sham-controlled cohorts.”
> “Cohort 4 is open-label.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.3-2"></a>

###### Design fields in the current registry record

| Field | Registry value |
| --- | --- |
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.3-3"></a>

###### Follow-up duration by cohort

> “Cohorts 1 and 2 participants continue follow-up visits through 6 years after receipt of AMT-130. Cohorts 3 and 4 participants continue follow-up visits through 5 years after receipt of AMT-130.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.3-4"></a>

###### Randomized, quadruple-masked parallel design with an 18-month core period: registry version 1, October 2019, superseded

| Field | Registry value |
| --- | --- |
| Official title | “A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington Disease” |
| Interventional study model | “Parallel Assignment” |
| Masking | “Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)” |
| Allocation | “Randomized” |
| Enrollment | “26 [Estimated]” |

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

> “CT-AMT-130-01 is a Phase I/II, randomized, multicenter, dose escalation, double-blind, imitation surgery, first-in-human (FIH) study.”
> “This 5-year trial consists of a blinded 18-month Core Study Period to evaluate the safety and potential impact of AMT-130 on disease progression and an unblinded 3.5-year Long-Term Period with annual follow-up visits to evaluate the safety of AMT-130 and disease progression.”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="topic-3.1.2.3-5"></a>

###### Randomized, triple-masked sequential design with crossover: registry version 33, October 2024, superseded

| Field | Registry value |
| --- | --- |
| Version | “Viewing V33 (2024-10-22)” |
| Interventional study model | “Sequential Assignment” |
| Masking | “Triple (Participant, Investigator, Outcomes Assessor)” |
| Allocation | “Randomized” |
| Enrollment | “37 [Estimated]” |

Source: [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33)

> “Cohort 1 & 2 consists of a blinded 12-month Core Study Period to evaluate the safety and potential impact of AMT-130 on disease progression and an unblinded 4-year Long-Term Period with periodic follow-up visits to evaluate the safety of AMT-130 and disease progression in treated individuals.”
> “Cohort 2 Sham participants who do not cross over to receive AMT-130 treatment will have the opportunity to participate in the Optional Extended Follow-Up Period and will be followed for an additional 2 years.”
> “Following completion of the 12-month blinded post treatment follow-up period (Cohorts 1 & 2 only), once the crossover has been activated after review of data by the DSMB, subjects randomized to the imitation (sham) procedure who continue to meet inclusion/exclusion criteria will be allowed to crossover to receive AMT-130 treatment.”
> “Cohort 3 participants will receive either high or low dose AMT-130. Following completion of the Month 36 visit, they will be unblinded to their treatment arm.”

Source: [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33)

<a id="topic-3.1.2.3-6"></a>

###### Blinded core period of 18 months at first dosing, June 2020, superseded

> “The five-year, multi-center trial consists of a blinded 18-month core study period followed by unblinded long-term follow-up.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.3-7"></a>

###### Blinded 12-month core period followed by five years of follow-up, March 2022

> “The Phase I/II clinical trial consists of a blinded 12-month period followed by unblinded long-term follow-up for five years.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.3-8"></a>

###### Cohort 3 as first planned: alternative stereotactic navigation, December 2021, superseded in June 2023

> “uniQure also plans to initiate a third cohort in the ongoing U.S. Phase I/II clinical trial in the second half of 2022 that will explore the use of alternative stereotactic navigation systems to simplify placement of catheters for infusions of AMT-130.”
> “This will be explored in two steps and include up to 18 additional randomized patients who will receive the higher dose of 6x1013 vg.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.3-9"></a>

###### Cohort 3 redesigned to study perioperative immunosuppression, June 2023

> “In the second half of 2023, uniQure expects to initiate a third cohort in the ongoing U.S. clinical trial to further investigate both doses in combination with perioperative immunosuppression with a focus on evaluating near-term safety.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.3-10"></a>

###### Cohort 3: blinded randomization to high or low dose

> “Patients were blinded and randomized to receive either the high (n=6) or low dose (n=6) of AMT-130 in conjunction with an immunosuppression regimen.”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-3.1.2.3-11"></a>

###### Cohort 4: high dose in participants with lower striatal volumes

> “Q3 2025: Initiate a fourth cohort evaluating high-dose AMT-130 in six patients with lower striatal volumes compared to those of patients enrolled in previous cohorts.”

Source: [uniQure press release, second quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2025-financial-results-and)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria in the current registry record

> “Participants 25 to 65 years of age of both sexes”
> “Early manifest HD as defined by a UHDRS total functional capacity (TFC) score of 9 to 13 and EITHER a diagnostic confidence level (DCL) of 4 OR a DCL of 3 if the subject either meets the definition of multidimensional manifest HD (UHDRS question 80) or has cognitive symptoms”
> “Cohort 3: Early manifest HD as defined by a UHDRS TFC score of ≥ 11”
> “HTT gene expansion testing with the presence of ≥40 CAG repeats”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.4-2"></a>

###### Striatal volume criteria: minimum volumes in Cohorts 1 to 3 and lower volumes in Cohort 4

> “Cohorts 1, 2, & 3: Putamen ≥2.5 cm^3 (per side); Caudate ≥2.0 cm^3 (per side)”
> “Cohort 4: Putamen <2.5 cm^3 (on either side); Caudate <2.0 cm^3 (on either side)”
> “Cohort 4 ONLY: Inability to establish a safe trajectory to administer AMT-130 to the target structures, as assessed by neuroimaging.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.4-3"></a>

###### Selected exclusion criteria in the current registry record

> “Evidence of suicide risk”
> “Presence of an implanted deep brain stimulation device, ventriculoperitoneal or other CSF shunt, or other implanted catheter”
> “Brain and spinal pathology that may interfere with the surgical delivery of AMT-130 or represents a significant neurologic comorbid disorder”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.4-4"></a>

###### Eligibility in the original registry record, October 2019, superseded

> “First 4 subjects in Cohort 1: early manifest HD (Stage 2). All remaining subjects in Cohort 1 and all subjects in Cohort 2: early manifest HD (Stages 1 and 2).”
> “HTT gene expansion testing with the presence of ≥44 CAG repeats.”
> “Striatal MRI volume requirements per hemisphere: Putamen ≥2.5 cm3 (per side); Caudate ≥2.0 cm3 (per side)”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Doses and route in the current registry record

> “Low dose rAAV5-miHTT (6x10^12 gc/subject).”
> “High dose rAAV5-miHTT (6x10^13 gc/subject).”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.5-2"></a>

###### Imitation (sham) surgery in Cohorts 1 and 2

> “Simulated surgical procedure with skin incisions only; no intrastriatal injections and no burr holes through the skull”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.5-3"></a>

###### Imitation surgery with partial-thickness burr holes: registry version 1, October 2019, superseded

> “Imitation surgery patients randomized across both Cohort 1 and 2”
> “Bilateral partial thickness burr holes placed, no intrastriatal injections”
> “Intrastriatal administration of low dose rAAV5-miHTT (6E12 gc/subject). Single dose administration.”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="topic-3.1.2.5-4"></a>

###### Treatment allocation in Cohorts 1 and 2

> “In the U.S. study, 26 patients with early manifest Huntington’s disease were randomized to treatment (six low-dose patients, 10 high-dose patients) or an imitation (sham) surgical procedure (10 patients).”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.2.5-5"></a>

###### Administration procedure in Cohorts 1 and 2

> “The treated patients have received a single administration of AMT-130 using MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.5-6"></a>

###### Cohort 3: established administration procedure

> “The third cohort will enroll up to 10 patients, all of whom will receive AMT-130 using the current, established stereotactic neurosurgical delivery procedure.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.5-7"></a>

###### Cohort 4: high dose with perioperative dexamethasone

> “All participants in Cohort 4 will receive high dose AMT-130 and will receive pre- and post-operative dexamethasone.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary outcome: number and type of adverse events at 12 months

> “Safety will be assessed by adverse events (AEs) related to clinical safety laboratory tests, vital signs, electrocardiograms (ECGs), neurological and physical examinations, rAAV5 vector shedding, immunogenicity response”
> “12 months (Cohorts 1 & 2) and 12 months (Cohort 3)”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.6.1-2"></a>

###### First-in-human trial with staged dosing reviewed by the Data Safety Monitoring Board

> “Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease”
> “The first two patients will be observed for an initial period of 90 days, followed by a meeting of the Data Safety Monitoring Board (DSMB).”
> “The DSMB will review the data on the first two patients and make a determination about continued dosing of the next patients.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.6.1-3"></a>

###### Secondary outcome: persistence of AMT-130 in the brain

> “Duration of persistence of AMT-130 in the brain”
> “Change over time in levels of AMT-130-derived Vector DNA Expression in the Cerebrospinal Fluid (CSF)”
> “Collected for duration of study through month 72 (Cohorts 1 & 2) and through month 16 (Cohorts 3 & 4)”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.6.1-4"></a>

###### Exploratory outcomes in the current registry record

| Exploratory outcome | Registry entry |
| --- | --- |
| Cerebrospinal fluid mutant huntingtin | “CSF Mutant Protein (fM)” |
| Neurofilament light chain | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Rating scale | “Unified Huntington Disease Rating Scale (UHDRS)” |
| Quantitative motor testing | “Quantitative Motor (Q-Motor) Testing” |
| Imaging | “Magnetic Resonance Imaging (MRI)” |
| Health-related quality of life | “Neuro-QoL Measures” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

> “Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment.”
> “The UHDRS will assess changes from baseline in summary scores of domains of motor function, cognitive function, behavioral function, and functional abilities.”
> “MRI assessments will include whole brain volume, striatal region volumes, white matter volume, gray matter volume, ventricular volume, cortical thickness, and diffusion MRI measures.”
> “The Neuro-QoL is a brief, reliable, valid, standardized set of patient reported, Health Related Quality of Life (HRQoL) measures for people living with neurological conditions.”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-3.1.2.6.1-5"></a>

###### Additional exploratory outcomes in registry version 1, October 2019

> “The HD-CAB measures cognitive dysfunction in late premanifest and early manifest HD patients.”
> “MRS will be collected using single-voxel point resolved spectroscopy of the left putamen and white matter region immediately adjacent to the left putamen.”
> “The HDQLIFE is a measurement system that was designed to provide a brief, reliable and valid assessment of HRQoL in HD and consists of NeuroQoL measures that have been validated in the HD population and several new HD specific measures.”
> “The HADS is a 14-item, self-report measure that has been shown to be reliable and valid for identifying depression and anxiety in adults who are physically ill.”

Source: [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1)

<a id="topic-3.1.2.6.1-6"></a>

###### Limitation of cerebrospinal fluid mutant huntingtin as a measure of brain levels

> “Given AMT-130 is directly administered deep within the brain, the pharmacodynamics of mHTT in the CSF are not believed to be materially representative of mHTT in the targeted brain regions.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment at first dosing, June 2020, superseded

> “The Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, tolerability, and efficacy signals in 26 patients with early manifest Huntington’s disease randomized to treatment with AMT-130 or an imitation (sham) surgery.”

Source: [uniQure press release, first patients treated (2020)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-two-patients-treated-phase-iii-clinical)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants in Cohorts 1 and 2 by arm

> “The first dose cohort includes 10 patients, of which six patients received treatment with AMT-130 and four patients received imitation surgery.”
> “The second dose cohort includes 16 patients, of which ten patients received treatment with AMT-130 and six patients received imitation surgery.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.7.1-3"></a>

###### Planned size of Cohort 3, December 2023

> “In the fourth quarter of 2023, the Company initiated patient dosing in a third cohort of up to 12 patients to further investigate both doses of AMT-130 in combination with perioperative immunosuppression, with a focus on evaluating near-term safety and tolerability.”

Source: [uniQure press release, full year 2023 results (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2023-financial-results-and-highlights-recent)

<a id="topic-3.1.2.7.1-4"></a>

###### Estimated total enrollment in the current registry record

| Field | Registry value |
| --- | --- |
| Enrollment (estimated) | “43” |

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Participants evaluable for biomarkers in the low-dose cohort, June 2022

> “Ten patients were evaluable for NfL measurements. Four treated and three control patients were evaluable for mHTT protein in the CSF measurements. The remaining two treated patients and one control patient did not have a measurable baseline CSF mHTT value.”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.7.2-2"></a>

###### Comparators and exclusion of crossover participants in the June 2023 interim analysis

> “Efficacy and biomarker data from the crossover patients are not included in the summary below.”
> “Clinical and functional measurements for treated patients in each dose cohort were compared to baseline measurements, control patients (up to 12 months) and a natural history cohort.”
> “The cohort includes 31 patients that met the uniQure clinical trial inclusion-criteria of CAG length, age, Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Enrollment progress, December 2021

> “Nineteen patients have been enrolled in the clinical trial to date, including 9 of 16 in the higher-dose cohort.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.1-2"></a>

###### Enrollment of Cohorts 1 and 2 completed, March 2022

> “today announced the completion of patient enrollment in the first two cohorts of its randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington’s disease.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="topic-3.1.2.8.1-3"></a>

###### Crossover of control participants, 2022 to 2023

> “One control patient from the higher-dose cohort was successfully crossed over to treatment in the third quarter of 2022 and received the lower dose of AMT-130.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

> “In the first quarter of 2023, a second control patient was crossed over to treatment and received the higher dose of AMT-130.”

Source: [uniQure press release, full year 2022 results (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2022-financial-results-and-highlights-recent)

> “Four of the six control patients in the high-dose cohort were crossed over to treatment and the remaining two patients failed to meet the study’s inclusion criteria.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="topic-3.1.2.8.1-4"></a>

###### Cohort 3 enrollment completed, February 2025

> “In February 2025, the Company completed enrollment of all 12 patients in the third cohort of the Phase I/II study.”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-3.1.2.8.1-5"></a>

###### Cohort 4 recruited in October 2025 and dosed in the fourth quarter of 2025

> “In October 2025, the Company initiated and fully recruited a fourth cohort evaluating high-dose AMT-130 in six patients with lower striatal volumes compared to patients in previous cohorts.”

Source: [uniQure press release, third quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and)

> “In the fourth quarter of 2025, dosing was completed in a fourth cohort of six patients receiving high-dose AMT-130 to evaluate safety and efficacy in patients with lower baseline striatal volumes compared to previous cohorts in the U.S. Phase I/II study.”

Source: [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### First four participants in the low-dose cohort, December 2021

> “The first four patients were a heterogeneous group representing a spectrum of Stage I-II early manifest disease with 41-44 CAG repeats, baseline Total Functional Capacity scores of 10-13 and Total Motor Scores of 7-23.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.2-2"></a>

###### Low-dose cohort of 10 participants, June 2022

> “The 10 patients enrolled in the low-dose cohort were all clinically diagnosed with early-stage Huntington’s disease with CAG repeats between 40-44, baseline Total Functional Capacity scores of 10-13, and Total Motor Scores of 7-23.”
> “Four patients were male and six were female with ages ranging from 34-58 years old. Demographics of the six treated patients were generally consistent with the four control patients.”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.2-3"></a>

###### Cohort 4 baseline characteristics

| Characteristic (mean or %) | AMT-130 high-dose Cohort 4 (n=6) |
| --- | --- |
| Sex, males (%) | “16.7” |
| Age | “43.7” |
| CAG repeats | “44.5” |
| DCL = 3, 4 (%) | “16.7, 83.3” |
| TFC | “12.0” |

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### First four participants at one year, December 2021

> “NfL increased as expected immediately following the AMT-130 surgical procedure and returned to baseline in the two treated patients. NfL remained relatively constant in the two untreated control patients.”
> “Measurements of total and mutant HTT protein in the cerebral spinal fluid of the four patients were highly variable and inconclusive.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.3-2"></a>

###### Low-dose cohort at 12 months: cerebrospinal fluid mutant huntingtin, June 2022

> “In the four treated patients with evaluable data, mean levels of CSF mHTT declined compared to baseline at all available timepoints. At 12 months after treatment, mean CSF mHTT decreased 53.8% compared to baseline (range 44% decrease to 71% decrease).”
> “In the three control patients with evaluable data, mean CSF mHTT showed an increase compared to baseline at one, three, six and nine months, and decreased by 16.8% compared to baseline at 12 months (range 35% increase to 47% decrease).”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.3-3"></a>

###### Low-dose cohort at 12 months: cerebrospinal fluid neurofilament light chain, June 2022

> “In the six treated patients, the increase in mean CSF NfL peaked one month after the surgical procedure. Thereafter, mean CSF NfL declined and at 12 months showed an 8% increase compared to baseline (range 46% increase to 14% decrease).”
> “In the four control patients, mean CSF NfL remained stable or slightly declined over 12 months (range 1% increase to 35% decrease).”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.3-4"></a>

###### U.S. interim analysis: clinical measures against baseline, controls, and a TRACK-HD natural history cohort, June 2023

> “Compared to baseline measurements, clinical function was generally preserved at 24 months for patients in the low-dose cohort and at 12 months for patients in the high-dose cohort.”
> “Total Motor Score (TMS): Low-dose patients demonstrated a mean improvement in TMS of 1.8 points at 24 months compared to natural history and high-dose patients demonstrated a mean improvement of 2.7 points at 12 months.”
> “Total Functional Capacity (TFC): Low-dose patients demonstrated a mean 0.8 point improvement in TFC at 24 months compared to natural history and high-dose patients demonstrated a mean 0.5 point improvement at 12 months.”
> “Composite Unified Huntington’s Disease Rating Scale (cUHDRS): Low-dose patients demonstrated a mean 0.9 point improvement in cUHDRS at 24 months compared to natural history and high-dose patients demonstrated a mean 1.0 point improvement at 12 months.”
> “Patients in the control group experienced a worsening of Total Motor Score at 12 months compared to baseline and natural history. TFC and cUHDRS was preserved in control patients at 12 months.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.8.3-5"></a>

###### U.S. interim analysis: biomarkers and brain volume, June 2023

> “Mean CSF NfL for the low-dose cohort was 12.9% below baseline compared to a predicted 22.9% increase in the natural history, with four of the five low-dose patients having CSF NfL levels below baseline.”
> “CSF NfL levels in the high-dose cohort were more variable through 12 months, with a mean increase of 51.5% compared to baseline. Four of the eight high-dose patients with at least 12 months of follow-up had NfL levels below baseline.”
> “In the control group, mean CSF NfL was relatively stable and was 6.83% below baseline at 12 months.”
> “CSF mHTT for the low-dose cohort remained below baseline with a mean reduction of 8.1% at 24 months. CSF mHTT for the high-dose cohort was significantly more variable with a mean increase of 39.7% above baseline at 12 months compared to a 4.7% increase in the control group.”
> “The mean total brain volume for the control, low-dose and high-dose cohorts declined 0.74%, 1.02% and 1.23%, respectively at 12 months and were not significantly different from each other or from the natural history.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.8.3-6"></a>

###### Cohort 3: perioperative neurofilament light chain

> “Perioperative changes in CSF NfL were consistent with previously reported observations, reinforcing their association with the surgical administration.”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### First four participants at one year, December 2021

> “There have been no serious adverse events (SAEs) to date related to AMT-130 in these patients.”
> “Structural magnetic resonance imaging did not reveal any clinically meaningful safety findings in either treated or control patients at one year of follow-up.”

Source: [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="topic-3.1.2.8.5-2"></a>

###### Low-dose cohort at 12 months: deep vein thrombosis and postoperative delirium, June 2022

> “No serious adverse events related to AMT-130 were reported in these patients. Two serious adverse events unrelated to AMT-130 occurred: a deep-vein thrombosis in the elbow in one patient that resolved with anticoagulants and transient post-operative delirium in a second patient that was resolved through supportive care.”
> “No adverse drug reactions or serious unexpected adverse reactions were reported.”

Source: [uniQure press release, low-dose cohort update (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-low-dose-cohort-phase-iii-clinical)

<a id="topic-3.1.2.8.5-3"></a>

###### High-dose procedures paused after suspected unexpected serious adverse reactions, August 2022

> “In July, we reported to the health authorities suspected unexpected severe adverse reactions in three of the 14 patients treated with the higher dose of AMT-130”
> “A third patient, who had previously been treated with the higher-dose of AMT-130 in the U.S. during March 2022, experienced severe headache and other related symptoms soon after AMT-130 administration that was initially deemed by the investigator as not related to AMT-130 but related to the procedure.”
> “Upon further review and discussion with the clinical trial’s independent Data Safety Monitoring Board (DSMB) following the events observed in the European study, the Company has reclassified and reported the patient reaction in the U.S. trial as a SUSAR.”

Source: [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)

<a id="topic-3.1.2.8.5-4"></a>

###### High-dose treatment resumed with additional monitoring, October 2022

> “In October 2022, the DSMB reviewed all available safety, biomarker and imaging data from the ongoing Phase I/II clinical trials of AMT-130 and recommended resuming treatment at the higher dose.”
> “The DSMB recommended implementing additional risk mitigation procedures during the first two weeks after the surgical administration of AMT-130, including a seven-day, in-person post-surgical visit.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-3.1.2.8.5-5"></a>

###### U.S. interim analysis: serious adverse events and suspected unexpected serious adverse reactions, June 2023

> “The most common adverse events in the treatment groups were related to the surgical procedure. No treatment emergent adverse events (TEAEs) led to discontinuation of patient follow-up.”
> “As previously reported, there were two serious adverse events (SAE) unrelated to AMT-130 (post-operative delirium and major depression) in the low-dose cohort, one SAE in the high-dose cohort (back pain), and one SAE (deep vein thrombosis) in the control group. In addition there were two suspected unexpected serious adverse events (severe headache, central nervous system inflammation) in the high-dose cohort. All the events have resolved.”
> “Following a review of the interim data analysis, the Data Safety Monitoring Board (DSMB) for the U.S. Phase I/II clinical trial concluded there are no safety concerns with either dose and recommended continuing clinical development of AMT-130.”

Source: [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130)

<a id="topic-3.1.2.8.5-6"></a>

###### Cohort 3: serious adverse events related to immunosuppression

> “AMT-130 was generally well-tolerated at both dose levels;”
> “No treatment-related serious adverse events were reported;”
> “Three serious adverse events related to immunosuppression (mania, infection, and fever) were observed; all resolved fully with supportive care and;”

Source: [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-3.1.2.8.5-7"></a>

###### Cohort 4: treatment-related central nervous system inflammation

> “One treatment-related SAE of CNS inflammation in a Cohort 4 patient, fully resolved following a short course of corticosteroids”

Source: [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- Changed blinding and registry inconsistencies: the current ClinicalTrials.gov record lists allocation as non-randomized and masking as none (open label), while its official title describes a randomized, double-blind, sham control and open-label study. Version 1 (2019) listed a randomized, quadruple-masked design with an estimated enrollment of 26 and a blinded 18-month core period; version 33 (2024) listed a randomized, triple-masked design with an estimated enrollment of 37 and a blinded 12-month core period; the current record lists an estimated enrollment of 43. Cohort 4 is open-label.
- Short randomized comparison: the sham comparison in Cohorts 1 and 2 covered the blinded 12-month period, after which sham participants could cross over. Four of the six control participants in the high-dose cohort crossed over and the other two did not meet the inclusion criteria, and interim analyses compared treated participants with control participants only up to 12 months and excluded efficacy data from crossover participants.
- Small numbers: Cohorts 1 and 2 randomized 26 participants (six low dose, 10 high dose, 10 sham); Cohort 3 enrolled 12 and Cohort 4 six.
- Safety as the primary outcome: the study is designed to establish safety and proof-of-concept, and the registered primary outcome is adverse events at 12 months.
- Target engagement: the company states that CSF mutant huntingtin is not believed to be materially representative of mutant huntingtin in the targeted brain regions, and one commentary noted that there are no data on mutant HTT lowering.
- Protocol changes: version 1 required ≥44 CAG repeats and an imitation surgery with bilateral partial thickness burr holes; the current record requires ≥40 CAG repeats and a simulated procedure with skin incisions only and no burr holes. Cohort 3 was first planned to study alternative stereotactic navigation systems and was redesigned to study perioperative immunosuppression.

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493); [ClinicalTrials.gov NCT04120493 version 1](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=1); [ClinicalTrials.gov NCT04120493 version 33](https://clinicaltrials.gov/study/NCT04120493?tab=history&a=33); [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene); [uniQure press release, U.S. interim data (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and); [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent); [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/); [uniQure press release, clinical update on first patients (2021)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-clinical-update-first-patients-phase-iii)

<a id="heading-3.1.3"></a>

#### 3.1.3 CT-AMT-130-02

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Primary and secondary objectives in the EU Clinical Trials Register

> “Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult participants with early manifest HD”
> “Determine the duration of persistence of AMT-130 in the brain”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.1-2"></a>

###### Expanding exposure to both doses after the U.S. study

> “The aim of the European study is to build upon the safety demonstrated in the first human dose (FHD) randomized, double blind, sham-controlled sequential dose escalation study (CT-AMT-130-01; clinicaltrials.gov NCT04120493) being conducted in the US and expand the number of patients exposed to the two doses to provide sufficient sample size for comparisons of safety and efficacy.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.1-3"></a>

###### Dose selection for later development, March 2022

> “Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into a pivotal study or into a confirmatory study should an accelerated registration be feasible.”

Source: [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Sites in Poland, the United Kingdom, and Germany at first dosing, February 2022

> “The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.”
> “The study is currently open for recruitment at IPiN and surgery at INC in Poland and is expected to expand to referral and surgical sites in the United Kingdom and Germany.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="topic-3.1.3.2-2"></a>

###### Study sites and dates in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Site, Warsaw, Poland | “Instytut Psychiatrii i Neurologii” |
| Site, Warsaw, Poland | “Interventional Neuro Center” |
| Site, Cardiff, United Kingdom | “Cardiff University” |
| Site, London, United Kingdom | “National Hospital for Neurology & Neurosurgery” |
| Study start (actual) | “2021-10-07” |
| Primary completion (estimated) | “2029-03” |
| Study completion (estimated) | “2029-10-07” |

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.2-3"></a>

###### EU trial record after transition to the Clinical Trials Regulation

| Field | Record value |
| --- | --- |
| Protocol code | “CT-AMT-130-02” |
| Transition trial | “Yes” |
| Locations | “Poland” |
| Start of trial | “Start of trial 07/10/2021” |
| Current status in Poland | “Ongoing, recruitment ended” |
| Recruitment end in Poland | “15/10/2024” |
| Estimated global end date | “31/12/2029” |

Source: [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Open-label Cohorts 1 and 2 and randomized Cohort 3 in the current registry record

> “CT-AMT-130-02 is a Phase Ib/II open-label (Cohorts 1 & 2), randomized (Cohort 3 only) sequential multiple dose study that will be conducted in approximately 5 to 8 European HD centers; 2 of these centers will serve as surgical sites.”
> “Both studies will share a common set of clinical, safety, imaging, and biomarker evaluations over 5 years of follow-up.”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.3-2"></a>

###### Design fields in the current registry record

| Field | Registry value |
| --- | --- |
| Official title | “A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease” |
| Allocation | “Randomized” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.3-3"></a>

###### Non-randomized, open-label ascending-dose design: registry version 1, February 2022, superseded

| Field | Registry value |
| --- | --- |
| Version | “Viewing V1 (2022-02-07)” |
| Official title | “A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington Disease” |
| Masking | “None (Open Label)” |
| Allocation | “Non-Randomized” |
| Enrollment | “15 [Estimated]” |

Source: [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1)

> “The first cohort will be treated with low dose, and a total of 6 enrolled participants is anticipated. The second cohort will be treated with high dose, and a total of 9 enrolled participants is anticipated.”

Source: [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1)

<a id="topic-3.1.3.3-4"></a>

###### Trial design fields in the EU Clinical Trials Register

| Field | Register value |
| --- | --- |
| Controlled | “No” |
| Randomised | “No” |
| Open | “Yes” |
| Double blind | “No” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.3-5"></a>

###### Six-month post-treatment period followed by five years of follow-up

> “The multi-center study consists of an initial 6-month post-treatment study period followed by long-term follow-up for five years.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria in the EU Clinical Trials Register

> “Male and female participants 25 to 65 years of age.”
> “Cohorts 1 & 2: Early manifest HD as defined by a UHDRS TFC score of 9 to 13 and EITHER”
> “Cohort 3: Early manifest HD as defined by a UHDRS TFC score of ≥11 and EITHER”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.4-2"></a>

###### Genetic and striatal volume criteria in the current registry record

> “HTT gene expansion testing with the presence of ≥40 CAG repeats (confirmed by genetic testing at central laboratory).”
> “Putamen ≥2.5 cm3 (per side)”
> “Caudate ≥2.0 cm3 (per side)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.4-3"></a>

###### Exclusion criteria: suicide attempt within 1 year

> “Suicide attempt within 1 year prior to Screening (Visit 1/1A)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.4-4"></a>

###### Same early manifest criteria as the U.S. study

> “The multi-center, open-label, Phase I/II clinical trial of AMT-130 being conducted in Europe and the UK enrolled a total of 13 patients with the same early manifest criteria for Huntington’s disease as the U.S. study.”

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Doses by cohort in the current registry record

> “Low dose AMT-130 (6 × 10^12 gc/subject)”
> “High dose AMT-130 (6 × 10^13 gc/subject)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.5-2"></a>

###### Investigational product concentration in the EU Clinical Trials Register

| Field | Register value |
| --- | --- |
| Concentration number | “2 x 10e13 gc/mL” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.5-3"></a>

###### All participants dosed with AMT-130

> “All patients will be dosed with AMT-130.”
> “Patients will receive a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Safety Measures as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Integrated two-study program with staggered enrollment under one safety board

> “This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.”
> “The DSMB will evaluate safety and other parameters to enable the staggered treatment of patients within each of the dosing cohorts”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.6.1-2"></a>

###### Primary outcomes at 6 months in the ClinicalTrials.gov record

> “Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Adverse Events”
> “Type and incidence of Adverse Events (AEs)”
> “Change over time in microglial activation (YKL-40) (pg/mL)”
> “Change over time in antibodies against AAV5 (g/L)”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-3.1.3.6.1-3"></a>

###### Primary end points in the EU Clinical Trials Register

> “Prospective assessment of suicidality via the Columbia-Suicide Severity Rating Scale (C-SSRS).”
> “Change from baseline to Day 14 and Month 1 in the Montreal Cognitive Assessment (MoCA)”
> “Change from baseline in edema, inflammation, volume loss, and structural changes as measured by the following MRI pulse sequences: T1, T2, and diffusion MRI (dMRI).”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-3.1.3.6.1-4"></a>

###### Secondary end points: vector DNA and miRNA expression in cerebrospinal fluid

> “Change over time in levels of AMT-130-derived vector DNA and miRNA expression in the CSF in Cohorts 1 and 2 through approval of CT-AMT-130-02 Protocol Amendment 6.0 Version 7.0.”
> “Change over time in levels of only AMT-130 derived vector DNA in Cohorts 1 and 2 post-approval and throughout the trial in Cohort 3.”

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment of 15 participants in two open-label cohorts, February 2022

> “The European Phase Ib/II clinical trial of AMT-130 for the treatment of Huntington’s disease will explore the safety, proof of concept, and dosing in 15 total patients with early manifest Huntington’s disease split into a six person, low-dose open-label cohort, followed by a nine patient, higher-dose open-label cohort.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants enrolled and treated by dose

> “In the European study, 13 patients were enrolled and treated with AMT-130 (six low-dose patients and seven high-dose patients).”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-3.1.3.7.1-3"></a>

###### Actual enrollment in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Enrollment (actual) | “14” |

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### First two participants dosed, February 2022

> “today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.”

Source: [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label)

<a id="topic-3.1.3.8.1-2"></a>

###### Participants treated, November 2022

> “To date, 10 patients have been treated in the European study, including all six patients in the lower-dose cohort and four of nine patients in the higher-dose cohort.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-3.1.3.8.1-3"></a>

###### Enrollment completed in June 2023

> “We completed the enrollment of all 26 patients in the first two cohorts of the U.S. study in March 2022 and the enrollment of 13 patients in the first two cohorts of the European study in June 2023.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Suspected unexpected serious adverse reactions in two high-dose participants at one site, July 2022

> “In mid-July, the Company reported to the appropriate regulatory agencies suspected unexpected severe adverse reactions (SUSARs) in two patients that were treated with the higher-dose of AMT-130 at a single clinical site in the European Phase Ib/II study.”
> “Both patients presented with localized inflammatory responses and other related symptoms approximately one to two weeks after their procedures.”
> “All three patients have fully or substantially recovered after treatment and have been released from the hospital.”

Source: [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)

<a id="topic-3.1.3.8.5-2"></a>

###### Plan to resume dosing in the European study, November 2022

> “The Company plans to resume patient dosing in the open-label European clinical study as soon as possible and complete enrollment in the first half of 2023.”

Source: [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and)

<a id="topic-3.1.3.8.5-3"></a>

###### Safety notifications in the EU trial record

| Notification | Record value |
| --- | --- |
| Serious breach | “Serious Breach (0)” |
| Unexpected event | “Unexpected Event (0)” |
| Urgent safety measure | “Urgent Safety Measure (0)” |
| Temporary halt | “Temporary Halt (0)” |

Source: [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

- Open-label, uncontrolled design with inconsistent records: the EU Clinical Trials Register lists the trial as not controlled, not randomised, open, and not double blind. The ClinicalTrials.gov record describes open-label Cohorts 1 and 2 and randomization in Cohort 3 only, lists allocation as randomized and masking as none (open label), and gives an official title describing a randomized, double-blind study; version 1 (2022) listed a non-randomized, open-label design with an estimated enrollment of 15.
- Enrollment: 15 participants were planned (six low dose, nine high dose). The Form 10-K reports 13 participants enrolled and treated (six low dose, seven high dose), while the ClinicalTrials.gov record lists an actual enrollment of 14.
- Sites: the February 2022 release named sites in Poland, the United Kingdom, and Germany; the ClinicalTrials.gov record lists sites in Poland and the United Kingdom, and the CTIS record lists Poland.
- Results reporting: the pooled-analysis protocols pool data across the U.S. and EU studies, and the registered primary outcomes are safety and tolerability measures, including adverse events.
- Safety: suspected unexpected severe adverse reactions occurred in two high-dose participants treated at a single clinical site.

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL); [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017); [ClinicalTrials.gov NCT05243017 version 1](https://clinicaltrials.gov/study/NCT05243017?tab=history&a=1); [uniQure press release, first European patients dosed (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-dosing-first-patients-european-open-label); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [CTIS 2024-511766-37-00](https://euclinicaltrials.eu/ctis-public/view/2024-511766-37-00); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and)

<a id="heading-3.1.4"></a>

#### 3.1.4 Planned Confirmatory Trial

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

No evidence found.

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Screening to begin in the United States by the end of 2026

> “The Company plans to initiate patient screening in the U.S. by the end of 2026.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

> “The Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized, standard-of-care-controlled design, November 2026

> “The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) as the primary endpoint at 36 months.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-3.1.4.3-2"></a>

###### Standard-of-care control considered after the June 2026 Type B meeting, July 2026

> “In addition, the FDA seeks to align on the confirmatory study design prior to the BLA submission, including consideration of a randomized standard-of-care control design instead of a sham procedure.”
> “The Company plans to initiate the confirmatory study as expeditiously as possible after aligning with the FDA on the trial design.”

Source: [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and)

<a id="topic-3.1.4.3-3"></a>

###### Sham surgery-controlled study recommended after the January 2026 Type A meeting, superseded in June 2026

> “In January 2026, we met with the FDA at a Type A meeting to discuss AMT-130.”
> “The FDA strongly recommended we conduct a prospective, randomized, double-blind, sham surgery-controlled study.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Ifezuntirgene inilparvovec or standard of care, randomized 2:1

> “The study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Total Functional Capacity as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Total Functional Capacity in the phase I/II data at 48 months

> “Total Functional Capacity (TFC), the primary measure for the confirmatory study, showed a 61% slowing (nominal p=0.008) at 48 months.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-3.1.4.6.1-2"></a>

###### Rate of decline by baseline Total Functional Capacity

> “The annual rate of decline for 575 patients with baseline TFC scores of 7 to 13 was 0.97 (SE 0.06), was 0.38 (SE 0.08) for 270 patients with baseline TFC scores of 3 to 6, and was 0.06 (SE 0.1) for 101 patients with TFC scores of 0 to 2.”
> “These rates of functional decline and the covariates that modify them should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease.”

Source: [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)

<a id="topic-3.1.4.6.1-3"></a>

###### Absence of placebo response on Total Functional Capacity: GENERATION HD1 placebo arm

> “The progression measured by Total Functional Capacity (TFC) in the GENERATION HD1 placebo arm aligned with predicted natural history (within 95% CI), indicating no significant placebo response.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-3.1.4.6.1-4"></a>

###### Functional ability as a regulatory outcome and ceiling effects in early disease

> “The assessment of functional ability as a clinical outcome is deemed essential for therapeutic approval by regulatory agencies such as the FDA.”
> “In addition, these scales have limiting ceiling effects that make them unattractive for use in earlier stages of HD.”

Source: [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)

<a id="topic-3.1.4.6.1-5"></a>

###### Total Functional Capacity at 65 weeks as the main measure of effectiveness in the Nurzigma application

> “The company presented results from a main study involving 499 adults aged 25 years and older with early Huntington’s disease.”
> “The main measure of effectiveness was the change in the total functional capacity (TFC) score after 65 weeks of treatment.”
> “The TFC score measures how well a person with a disease that affects the nervous system can perform daily tasks and activities.”

Source: [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)

<a id="topic-3.1.4.6.1-6"></a>

###### Internal consistency of the UHDRS domains, including functional capacity

> “The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity.”
> “We found there was a high degree of internal consistency within each of the domains of the UHDRS and that there were significant intercorrelations between the domains of the UHDRS, with the exception of the total behavioral score.”

Source: [Huntington Study Group (1996)](https://pubmed.ncbi.nlm.nih.gov/8684382/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Approximately 200 participants planned

> “The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Function Capacity (“TFC”) as the primary endpoint at 36 months.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

- Planned design only: the trial is described in company releases and the Form 10-Q as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint, and screening is planned to begin in the United States by the end of 2026.
- Control without a sham procedure: after a Type A meeting in January 2026 the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; in 2026 it later sought alignment on a confirmatory design that included consideration of a randomized standard-of-care control instead of a sham procedure.
- Primary endpoint: the UHDRS TFC appears to have a ceiling effect in early stage Huntington's disease, and it lacks core clinimetric data on test-retest reliability and internal consistency.
- Timing: the FDA stated that the confirmatory study should be well underway, and potentially fully enrolled, at the time of accelerated approval; the company expects the study to be well underway by the time of potential approval.

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and); [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm); [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [Mestre et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6174516/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
